Integrated Wealth Concepts LLC Sells 7,945 Shares of Novo Nordisk A/S (NYSE:NVO)

Integrated Wealth Concepts LLC cut its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 24.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,082 shares of the company's stock after selling 7,945 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Novo Nordisk A/S were worth $2,158,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Victory Capital Management Inc. boosted its position in shares of Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after buying an additional 23,223 shares during the period. Norman Fields Gottscho Capital Management LLC boosted its position in Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock worth $5,482,000 after acquiring an additional 19,870 shares during the period. Bryn Mawr Capital Management LLC grew its stake in Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after acquiring an additional 30,420 shares in the last quarter. Versant Capital Management Inc acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $86,000. Finally, Talbot Financial LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth approximately $4,066,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of research analyst reports. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday. UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Hold" and an average target price of $135.00.

Novo Nordisk A/S Stock Performance

NVO stock traded up $2.50 during midday trading on Tuesday, hitting $65.12. 10,896,640 shares of the company traded hands, compared to its average volume of 6,145,640. The business has a 50 day simple moving average of $73.21 and a 200-day simple moving average of $89.01. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The stock has a market capitalization of $292.23 billion, a price-to-earnings ratio of 19.79, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were paid a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's dividend payout ratio is presently 49.54%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.